Teva Pharmaceutical Industries (NYSE:TEVA) Research Coverage Started at Oppenheimer

Oppenheimer began coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a report issued on Wednesday morning, MarketBeat reports. The firm issued an outperform rating and a $50.00 price objective on the stock.

TEVA has been the topic of several other research reports. Barclays increased their price objective on shares of Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. UBS Group lifted their target price on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a research note on Friday, September 4th. Piper Sandler increased their price target on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 28th. Leerink Partners began coverage on Teva Pharmaceutical Industries in a report on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 price target on the stock. Finally, Wall Street Zen cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Eleven investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $43.73.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $39.15 on Wednesday. The stock has a market capitalization of $45.62 billion, a PE ratio of 65.25, a price-to-earnings-growth ratio of 3.83 and a beta of 0.87. The business’s fifty day moving average price is $36.18 and its 200 day moving average price is $33.80. The company has a debt-to-equity ratio of 1.56, a current ratio of 0.88 and a quick ratio of 0.67. Teva Pharmaceutical Industries has a 12-month low of $18.27 and a 12-month high of $40.79.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. The firm had revenue of $4.14 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. Equities research analysts forecast that Teva Pharmaceutical Industries will post 1.94 EPS for the current year.

Insider Activity at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 367,600 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, September 18th. The stock was sold at an average price of $39.06, for a total transaction of $14,358,456.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Brian Savage sold 7,342 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, September 18th. The shares were sold at an average price of $38.85, for a total value of $285,236.70. Following the transaction, the insider owned 8,500 shares in the company, valued at approximately $330,225. This trade represents a 46.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 374,959 shares of company stock worth $14,644,285. 0.54% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Allworth Financial LP lifted its position in shares of Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after acquiring an additional 329 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Teva Pharmaceutical Industries by 51.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after purchasing an additional 345 shares during the period. Sage Rhino Capital LLC increased its stake in Teva Pharmaceutical Industries by 5.6% in the 1st quarter. Sage Rhino Capital LLC now owns 7,874 shares of the company’s stock worth $237,000 after purchasing an additional 417 shares in the last quarter. Envestnet Portfolio Solutions Inc. increased its position in shares of Teva Pharmaceutical Industries by 7.1% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 7,311 shares of the company’s stock worth $248,000 after acquiring an additional 483 shares in the last quarter. Finally, First Trust Advisors LP lifted its position in shares of Teva Pharmaceutical Industries by 5.9% in the 1st quarter. First Trust Advisors LP now owns 9,619 shares of the company’s stock valued at $290,000 after acquiring an additional 539 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders.

Teva’s specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms.